Back to search
FDAFDA · Food and drugs·Recall number D-0816-2026

Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), 50 mL Single-Dose GALAXY Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-9549-50.

Published September 9, 2026 · Recall initiated: August 6, 2026

Summary

FDA records drug Class II recall D-0816-2026, published September 9, 2026 and initiated August 6, 2026. Recalling firm: Baxter Healthcare Corporation; Status: Ongoing; Reported quantity: N/A; Lot: Lot # NC193689, Exp Date: 10/16/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email if CLINDAMYCIN PHOSPHATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CLINDAMYCIN PHOSPHATE
Manufacturer
Baxter Healthcare Corporation
Distributor
US Nationwide; Puerto Rico; and Chile.
Lot
Lot # NC193689, Exp Date: 10/16/2027.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), 50 mL Single-Dose GALAXY Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-9549-50. recalled?

Yes. FDA published recall D-0816-2026 on September 9, 2026. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CLINDAMYCIN PHOSPHATE.